Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul B Chapman

Showing results (1-10 of 147) with videos related to

Pageof 15
Sort By:
Cancer Chemotherapy and Biological Response Modifiers|April 22, 2003
Immunotherapy of melanomaPaul B Chapman
Journal of the National Comprehensive Cancer Network : JNCCN|September 26, 2009
Counterpoint: The case against adjuvant high-dose interferon-alpha for melanoma patientsPaul B Chapman
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 16, 2004
T-cell chauvinists versus antibody advocates--can't we all just get along?Paul B Chapman
Pigment Cell & Melanoma Research|February 5, 2010
Programming T cells for adoptive T cell transfer therapyPaul B Chapman
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 27, 2014
Treating metastatic melanoma in 2014: what just happened and what is next?Paul B Chapman
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 16, 2002
Vaccinating patients with autologous tumorPaul B Chapman
Seminars in Oncology|December 18, 2007
Melanoma vaccinesPaul B Chapman
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 30, 2013
Mechanisms of resistance to RAF inhibition in melanomas harboring a BRAF mutationPaul B Chapman
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 10, 2008
Combining a peptide vaccine with high-dose interleukin-2Paul B Chapman
Current Opinion in Investigational Drugs (London, England : 2000)|August 7, 2003
Vaccinating against GD3 ganglioside using BEC2 anti-idiotypic monoclonal antibodyPaul B Chapman
Pageof 15

Showing results (1-10 of 147) with videos related to

Sort By:
Pageof 15
Cancer Chemotherapy and Biological Response Modifiers|April 22, 2003
Immunotherapy of melanomaPaul B Chapman
Journal of the National Comprehensive Cancer Network : JNCCN|September 26, 2009
Counterpoint: The case against adjuvant high-dose interferon-alpha for melanoma patientsPaul B Chapman
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 16, 2004
T-cell chauvinists versus antibody advocates--can't we all just get along?Paul B Chapman
Pigment Cell & Melanoma Research|February 5, 2010
Programming T cells for adoptive T cell transfer therapyPaul B Chapman
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 27, 2014
Treating metastatic melanoma in 2014: what just happened and what is next?Paul B Chapman
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 16, 2002
Vaccinating patients with autologous tumorPaul B Chapman
Seminars in Oncology|December 18, 2007
Melanoma vaccinesPaul B Chapman
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 30, 2013
Mechanisms of resistance to RAF inhibition in melanomas harboring a BRAF mutationPaul B Chapman
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 10, 2008
Combining a peptide vaccine with high-dose interleukin-2Paul B Chapman
Current Opinion in Investigational Drugs (London, England : 2000)|August 7, 2003
Vaccinating against GD3 ganglioside using BEC2 anti-idiotypic monoclonal antibodyPaul B Chapman
Pageof 15